Literature DB >> 23409688

Overactive bladder symptoms, stress urinary incontinence and associated bother in women aged 40 and above; a Belgian epidemiological survey.

D de Ridder1, T Roumeguère, L Kaufman.   

Abstract

AIM: This Belgian epidemiological study aimed to assess the prevalence of overactive bladder (OAB) and stress urinary incontinence (SUI) and associated bother in a female primary care population.
METHODS: Data on OAB and SUI were prospectively collected among women ≥ 40 years by general practitioners (GP) during a regular visit for any reason. The validated Bladder Control Self-Assessment Questionnaire (B-SAQ) was used and complemented with a question on SUI and bladder bother. The presence of mild bladder control symptoms (BCS) was defined as an overall B-SAQ symptom score (OSS) ≥ 4 and an overall bother score (OBS) ≥ 1. Descriptive statistics were performed.
RESULTS: Data from 7139 women were analysed. About 33.9% had mild BCS. Most women reported overall mild OAB symptoms (46.9%) and 34.9% had moderate-to-(very) severe symptoms. The prevalence of moderate-severe urgency, frequency or nocturia was higher than that of moderate-severe incontinence. Urgency and nocturia were considered the most bothersome symptoms. Moderate-severe SUI affected 17.7% of women. About 16.4% of women reported to be moderately-severely bothered by their bladder in everyday life. The risk of severe symptoms and bother increased with age. About 10% of women had clinically significant BCS (OSS ≥ 7 and OBS ≥ 4).
CONCLUSIONS: In Belgian women ≥ 40 years visiting a GP for any reason, one in three had mild BCS and might benefit from further evaluation. Up to 10% of these women had clinically significant BCS for which medical therapy might be necessary. This warrants awareness for early diagnosis and intervention.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23409688     DOI: 10.1111/ijcp.12015

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  8 in total

1.  The "bother" of urinary incontinence.

Authors:  Gerda Trutnovsky; Daniela Ulrich; Rodrigo Guzman Rojas; Kristy Mann; Thomas Aigmueller; Hans P Dietz
Journal:  Int Urogynecol J       Date:  2014-02-11       Impact factor: 2.894

2.  Overactive bladder symptom severity, bother, help-seeking behavior, and quality of life in patients with type 2 diabetes: a path analysis.

Authors:  Dongjuan Xu; Meng Zhao; Liqun Huang; Kefang Wang
Journal:  Health Qual Life Outcomes       Date:  2018-01-02       Impact factor: 3.186

Review 3.  Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?

Authors:  John Heesakkers; Montserrat Espuña Pons; Philip Toozs Hobson; Emmanuel Chartier-Kastler
Journal:  Res Rep Urol       Date:  2017-10-31

4.  The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection.

Authors:  Kirill V Kosilov; Sergay A Loparev; Marina A Ivanovskaya; Liliya V Kosilova
Journal:  Arab J Urol       Date:  2015-08-05

5.  Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women.

Authors:  Kirill Kosilov; Sergey Loparev; Marina Ivanovskaya; Liliya Kosilova
Journal:  Int Neurourol J       Date:  2013-12-31       Impact factor: 2.835

6.  Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan.

Authors:  Chen-Li Cheng; Jian-Ri Li; Ching-Heng Lin; William C de Groat
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 7.  Recent advances in pharmacological management of urinary incontinence.

Authors:  Bronagh McDonnell; Lori Ann Birder
Journal:  F1000Res       Date:  2017-12-19

8.  Patient utilization survey of mirabegron prescribed for overactive bladder.

Authors:  Päivi Rahkola-Soisalo; Marcin Balcerzak; Jarno Ruotsalainen; Tomi S Mikkola
Journal:  Investig Clin Urol       Date:  2019-02-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.